These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28194539)

  • 21. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
    Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
    J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of temsirolimus and metformin in advanced solid tumours.
    MacKenzie MJ; Ernst S; Johnson C; Winquist E
    Invest New Drugs; 2012 Apr; 30(2):647-52. PubMed ID: 20978924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors.
    Semrad TJ; Eddings C; Dutia MP; Christensen S; Lara PN
    Anticancer Drugs; 2013 Jul; 24(6):636-40. PubMed ID: 23698253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
    Grilley-Olson JE; Bedard PL; Fasolo A; Cornfeld M; Cartee L; Razak AR; Stayner LA; Wu Y; Greenwood R; Singh R; Lee CB; Bendell J; Burris HA; Del Conte G; Sessa C; Infante JR
    Invest New Drugs; 2016 Dec; 34(6):740-749. PubMed ID: 27450049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
    Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Jones SF; Rasco D; Cox DS; Durante M; Bellew KM; Park J; Le NT; Infante JR
    Ann Oncol; 2015 Jan; 26(1):58-64. PubMed ID: 25344362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).
    Chiu JW; Hotte SJ; Kollmannsberger CK; Renouf DJ; Cescon DW; Hedley D; Chow S; Moscow J; Chen Z; Perry M; Diaz-Padilla I; Tan D; Hirte H; McWhirter E; Chen H; Siu LL; Bedard PL
    Invest New Drugs; 2016 Feb; 34(1):104-11. PubMed ID: 26686201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
    Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.
    Pearson AD; Federico SM; Aerts I; Hargrave DR; DuBois SG; Iannone R; Geschwindt RD; Wang R; Haluska FG; Trippett TM; Geoerger B
    Oncotarget; 2016 Dec; 7(51):84736-84747. PubMed ID: 27713169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
    Naing A; Kurzrock R; Burger A; Gupta S; Lei X; Busaidy N; Hong D; Chen HX; Doyle LA; Heilbrun LK; Rohren E; Ng C; Chandhasin C; LoRusso P
    Clin Cancer Res; 2011 Sep; 17(18):6052-60. PubMed ID: 21750201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
    Macarulla T; Cervantes A; Tabernero J; Roselló S; Van Cutsem E; Tejpar S; Prenen H; Martinelli E; Troiani T; Laffranchi B; Jego V; von Richter O; Ciardiello F
    Br J Cancer; 2015 Jun; 112(12):1874-81. PubMed ID: 25989270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
    Fouladi M; Perentesis JP; Wagner LM; Vinks AA; Reid JM; Ahern C; Thomas G; Mercer CA; Krueger DA; Houghton PJ; Doyle LA; Chen H; Weigel B; Blaney SM
    Clin Cancer Res; 2015 Apr; 21(7):1558-65. PubMed ID: 25467181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
    Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
    Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer.
    McHugh DJ; Chudow J; DeNunzio M; Slovin SF; Danila DC; Morris MJ; Scher HI; Rathkopf DE
    Clin Genitourin Cancer; 2020 Jun; 18(3):171-178.e2. PubMed ID: 32057715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
    Gadgeel SM; Lew DL; Synold TW; LoRusso P; Chung V; Christensen SD; Smith DC; Kingsbury L; Hoering A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1089-96. PubMed ID: 24057042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.
    Liu X; Kambrick S; Fu S; Naing A; Subbiah V; Blumenschein GR; Glisson BS; Kies MS; Tsimberidou AM; Wheler JJ; Zinner RG; Hong DS; Kurzrock R; Piha-Paul SA
    Oncotarget; 2016 Apr; 7(17):23227-38. PubMed ID: 26933802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.
    Mahadevan D; Mita M; Richards D; McClay E; Heist RS; Kumar A; Sundararajan S; Naing A
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):681-688. PubMed ID: 28289865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
    Lebbé C; Italiano A; Houédé N; Awada A; Aftimos P; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Raymond E; Faivre S; Pages C; Gomez-Roca C; Schueler A; Goodstal S; Massimini G; Delord JP
    Target Oncol; 2021 Jan; 16(1):47-57. PubMed ID: 33211315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
    Desar IM; Timmer-Bonte JN; Burger DM; van der Graaf WT; van Herpen CM
    Br J Cancer; 2010 Nov; 103(11):1637-43. PubMed ID: 21045832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.